Tissue Products and Kits From Renal Disease

肾病组织产品和试剂盒

• 批准号: 7289358
• 负责人: VERONIQUE L BARNES
• 金额: $ 29.9万
• 依托单位: PROBETEX, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-01 至 2009-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7289358
• 关键词: Address; Adult; American; Animal Experiments; Anti-Glomerular Basement Membrane Disease; Antibodies; Awareness; Biological Assay; Bos taurus; Businesses; Cattle; Cell Line; Clinical; Collaborations; Communities; Core Facility; Crescentic Glomerulonephritis; Custom; Data; Development; Diabetes Mellitus; Diabetic Nephropathy; Disease; Disease Progression; Disease model; Embryo; End stage renal failure; Endothelial Cells; Epithelial; Epithelial Cells; Experimental Models; Face; Feasibility Studies; Fostering; Freezing; Funding; Genomics; Glomerular Mesangial Cell; Glomerular basement membrane antibody; Glomerulonephritis; Goals; Grant; Histology; Human; Human Resources; Image; Immune; Immune Sera; Immunohistochemistry; In Situ Hybridization; Institutes; Interstitial Nephritis; Investigation; Kidney; Kidney Diseases; Kidney Failure; Label; Licensing; Lupus Nephritis; Marketing; Mediating; Medicine; Membranous Glomerulonephritis; Methods; Mission; Modeling; Molecular; Mus; Nephrology; Northern Blotting; Organ; Paraffin Tissue; Pathology; Phase; Physicians; Preparation; Process; Production; Proteins; Proteomics; Protocols documentation; Purpose; Quality Control; RNA; Range; Rate; Rattus; Reagent; Renal function; Renal glomerular disease; Reporting; Research; Research Personnel; Research Priority; Resources; Ribonucleases; Sampling; Scientist; Services; Sheep; Slide; Societies; Strategic Planning; Technology; Time; Tissue Microarray; Tissues; Today; Update; Validation; Western Blotting; Work; anti-Thy-1; commercialization; concept; embryonic stem cell; human disease; in vivo; innovation; kidney cell; metabolomics; prevent; repository; symposium

DESCRIPTION (provided by applicant): Kidney failure due to end-stage renal disease is escalating at an alarming rate, motivating renal investigators and clinicians to identify research priorities in search for better ways to prevent and treat kidney disease. There is a crucial need for increases in resources and manpower in research in kidney disease. An impediment to renal research has been dwindling resources and loss of protected time to devote to research in the face of an ever-increasing demand for further exploration of research ideas. There is a significant need and market potential for readily available reagents and tissue products from established models and human cases of renal disease. To address this deficit, Probetex was founded as a "Renal Research Resource Company" to create a repository of "off-the-shelf" tissue products to provide readily available samples and help investigators to quickly and efficiently explore their ideas on established and standardized models or identified cases of human disease. This Phase II application focuses on large-scale production of reagents and tissue products (tissue sections, protein lysates, purified RNA, and prefabricated Western and Northern blots) derived from the six models of kidney disease collectively representing the most common forms of renal disease presented clinically. These same products will be developed from normal and diseased human kidney. The models include 1. Mesangial Proliferative Glomeruonephritis (anti-Thy-1), 2. Immune-mediated Crescentic Glomerulonephritis and Interstitial Nephritis (anti-GBM), 3. Membranous Nephropathy (anti-Fx1A), 4. Lupus nephritis, 5. Type 1 and 6. Type 2 diabetic nephropathy. This grant will enable large-scale processing of existing lots of sheep antibodies developed to create reagents to induce three classical immune models of kidney disease (1-3 above). Also, manufacture of tissue products from the disease models will be processed for distribution as single units or in multiple arrays of tissue and prefabricated Western and Northern blots for comparison analysis of samples of different diseases or time points in the same application. Also, as part of Probetex's mission, the company, will prepare for commercialization seven kidney cell lines (embryonic stem cells and glomerular mesangial, epithelial, and endothelial cells). A plan to expand the scope of products through licensing and out-sourcing strategies will be implemented as part of the company's long-range goal. One of the main obstacles facing physician- and basic scientists today is dwindling resources and loss of protected time to devote to their research in the face of an ever increasing demand for further exploration of research ideas in kidney disease. Readily available samples derived from experimental models and clinical cases of renal disease are not commercially available. Probetex, Inc. was founded as a "Renal Research Resource Company" and addresses the above research priorities by fostering research in kidney function and pathology by means of providing reagents, products, and services for the investigation of experimental and clinical renal disease. Probetex's products will enable investigator-customers to quickly and efficiently explore their research ideas on established and standardized models and identified cases of human renal disease increasing awareness, resources and further research in kidney disease.

描述（由申请人提供）：终末期肾脏疾病引起的肾衰竭正在以惊人的速度升级，这促使肾脏研究者和临床医生确定研究重点，以寻找更好的预防和治疗肾脏疾病的方法。在肾脏疾病的研究中，迫切需要增加资源和人力。面对不断增长的对进一步探索研究思路的需求，肾脏研究的一个障碍是资源的减少和用于研究的受保护时间的丧失。从已建立的肾脏疾病模型和人类病例中获得的现成试剂和组织产品具有巨大的需求和市场潜力。为了解决这一问题，Probetex成立了一家“肾脏研究资源公司”，创建了一个“现成的”组织产品库，提供现成的样本，帮助研究人员快速有效地探索他们对已建立和标准化模型或已确定的人类疾病病例的想法。该II期申请的重点是大规模生产来自六种肾脏疾病模型的试剂和组织产品（组织切片、蛋白裂解物、纯化RNA和预制Western和Northern blots），这些模型共同代表了临床上最常见的肾脏疾病形式。这些相同的产品将从正常和患病的人类肾脏中开发出来。模型包括：1；2.系膜增生性肾小球肾炎（anti-Thy-1）；2 .免疫介导的新月状肾小球肾炎和间质性肾炎（抗gbm）；膜性肾病（抗fx1a）；狼疮性肾炎，5岁。输入1和6。2型糖尿病肾病。这笔拨款将使现有的大量绵羊抗体能够大规模处理，以创建试剂来诱导三种经典的肾脏疾病免疫模型（上文1-3）。此外，从疾病模型中生产的组织产品将被加工成单个单位或多个组织阵列，以及预制的Western和Northern blots，用于在同一应用中对不同疾病或时间点的样品进行比较分析。此外，作为Probetex使命的一部分，该公司将为7种肾细胞系（胚胎干细胞和肾小球系膜细胞、上皮细胞和内皮细胞）的商业化做准备。作为公司长期目标的一部分，将实施通过授权和外包战略扩大产品范围的计划。面对不断增长的对进一步探索肾脏疾病研究思路的需求，医生和基础科学家今天面临的主要障碍之一是资源的减少和用于研究的受保护时间的丧失。从肾脏疾病的实验模型和临床病例中获得的现成样品没有商业上的可用性。Probetex, Inc.成立时是一家“肾脏研究资源公司”，通过为实验和临床肾脏疾病的研究提供试剂、产品和服务，促进肾脏功能和病理的研究，解决上述研究重点。Probetex的产品将使研究者-客户能够快速有效地在已建立和标准化的模型上探索他们的研究想法，并确定人类肾脏疾病的病例，增加对肾脏疾病的认识，资源和进一步研究。

项目成果

Reciprocal induction of simple organogenesis by mouse kidney progenitor cells in three-dimensional co-culture.

三维共培养中小鼠肾祖细胞对简单器官发生的相互诱导。

• DOI: 10.1016/j.ajpath.2011.11.002
• 发表时间: 2012
• 期刊: The American journal of pathology
• 作者: Velagapudi,Chakradhar;Nilsson,Rune-Par;Lee,MyungJa;Burns,HannahS;Ricono,JillM;Arar,Mazen;Barnes,VeroniqueL;Abboud,HannaE;Barnes,JeffreyL
• 通讯作者: Barnes,JeffreyL